GNH USA

Europe — EMA

Mitomycin Accord

GNH USA supplies Mitomycin Accord (Mitomycin), an antibiotic for bladder, gastric, pancreatic and breast cancers. Request a quote for global supply.

Mitomycin

Request sourcing

1
Pack/s

What is Mitomycin?

Mitomycin, the active ingredient in Mitomycin Accord, is an antineoplastic antibiotic presented as an injectable solution for intravenous and intravesical use. It is employed in the treatment of several adult solid tumours, including bladder, gastric, pancreatic and breast cancers.

GNH USA supplies Mitomycin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical use across multiple regions. Its global distribution network ensures timely delivery and compliance with local import regulations.

What is Mitomycin used for?

Mitomycin is used in chemotherapy regimens targeting solid tumours and in intravesical therapy for bladder cancer. - Bladder cancer: intravesical administration reduces tumour recurrence after transurethral resection. - Gastric cancer: combined with other agents to improve response rates in advanced disease. - Pancreatic cancer: employed as part of multi‑drug protocols for metastatic cases. - Breast cancer: used in selected regimens for refractory or metastatic disease.

What are the side effects of Mitomycin?

Mitomycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported. - Myelosuppression: decreased white blood cells, platelets, and red cells. - Fatigue: generalized tiredness during treatment. - Mucositis: inflammation of the mouth and gastrointestinal lining. - Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects: - Hemorrhagic cystitis: bladder inflammation with possible bleeding. - Severe bone marrow failure: aplastic anemia or pancytopenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Renal impairment: acute kidney injury in susceptible patients.

What precautions apply to Mitomycin?

When using Mitomycin, clinicians should observe several safety measures to minimise risks. - Patient selection: avoid in patients with severe bone‑marrow suppression. - Renal function: assess creatinine clearance before initiating therapy. - Hepatic function: monitor liver enzymes during treatment. - Concomitant nephrotoxic or ototoxic drugs: use with caution. - Pregnancy and lactation: contraindicated unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

What does Mitomycin interact with?

Mitomycin can interact with other medicines, affecting its efficacy or toxicity.

Major Interactions (Avoid): - High‑dose radiation therapy: may increase risk of severe tissue damage. - Strong CYP450 inducers: may reduce plasma concentrations of Mitomycin. - Anticoagulants (e.g., warfarin): heightened bleeding risk due to bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Nephrotoxic agents (e.g., cisplatin): monitor renal function closely. - Other myelosuppressive chemotherapy: increased risk of cytopenias. - NSAIDs: may exacerbate gastrointestinal irritation.

Frequently asked questions

What is Mitomycin Accord used for?+
Mitomycin Accord is an injectable formulation of the antineoplastic antibiotic mitomycin. It is employed in chemotherapy protocols for solid tumours such as bladder, gastric, pancreatic and breast cancers, and it is also used intravesically to prevent recurrence of non‑muscle‑invasive bladder cancer after surgery.
How does mitomycin work?+
Mitomycin acts as a DNA cross‑linking agent. Inside cancer cells it is reduced to a reactive species that creates covalent bonds between guanine bases on DNA, blocking replication and transcription. This damage triggers programmed cell death, especially in rapidly dividing tumour cells, and its effect is amplified in hypoxic tumour environments.
What is the usual dose of Mitomycin Accord?+
The dose of Mitomycin Accord is determined by the prescribing oncologist based on the specific cancer type, treatment protocol, patient weight, renal function and prior therapy. Dosing regimens vary widely, and the prescriber will calculate the appropriate amount and schedule for each individual patient.
Is Mitomycin safe in pregnancy or breastfeeding?+
Mitomycin is classified as contraindicated during pregnancy and breastfeeding unless the potential benefit to the mother clearly outweighs the risk to the fetus or infant. Animal studies have shown embryotoxic effects, and there is insufficient human data, so it should be avoided in these populations whenever possible.
How do I order Mitomycin Accord from GNH USA?+
To order Mitomycin Accord, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details (including cold‑chain if needed) and assists with import documentation.
How does Mitomycin compare with the main alternative drug or class?+
Mitomycin belongs to the antineoplastic antibiotic class, whereas agents such as cisplatin or carboplatin are platinum‑based alkylating agents. Mitomycin’s DNA cross‑linking mechanism is distinct and it is often chosen for intravesical bladder therapy, while platinum compounds are more commonly used systemically. Toxicity profiles differ; mitomycin is associated with hemorrhagic cystitis, whereas platinum drugs frequently cause nephrotoxicity and ototoxicity.
How should Mitomycin Accord be stored and handled?+
Mitomycin Accord must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and do not freeze or shake vigorously. Before administration, allow the product to reach room temperature if required, and follow aseptic technique to avoid contamination.
How is Mitomycin Accord administered?+
Mitomycin Accord is given by intravenous infusion or intravesical instillation, depending on the indication. For systemic therapy, the drug is diluted in an appropriate carrier solution and infused over a prescribed period under medical supervision. For bladder cancer, a measured dose is instilled directly into the bladder and retained for a specified dwell time.
What are the most serious risks to watch for while receiving Mitomycin?+
The most serious risks include severe bone‑marrow suppression leading to pancytopenia, hemorrhagic cystitis with potential bladder bleeding, pulmonary toxicity such as interstitial pneumonitis, and acute renal impairment. Patients should be monitored regularly for blood counts, renal function, respiratory symptoms and urinary changes, and any severe adverse event should prompt immediate medical evaluation.
Who should not use Mitomycin Accord?+
Mitomycin Accord should be avoided in patients with pre‑existing severe bone‑marrow failure, uncontrolled infections, significant renal or hepatic dysfunction, and in pregnant or breastfeeding women unless no alternative exists. Individuals with known hypersensitivity to mitomycin or any component of the formulation should also not receive the product.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mitomycin
Route
Intravenous Use , Intravesical Use
Manufacturer
Accord Healthcare S.L.U.
Origin
EU

Related products

Mitomycin 20 mg/1

Mitomycin 20 mg/1

Mitomycin · 20 mg

Mitomycin
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Hikma Pharmaceuticals USA Inc.
USA
Mitomycin 40 mg/1

Mitomycin 40 mg/1

Mitomycin · 40 mg

Mitomycin
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Hikma Pharmaceuticals USA Inc.
USA
Mitomycin 20 mg/40mL

Mitomycin 20 mg/40mL

Mitomycin · 20 mg/40 mL

Mitomycin
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Hikma Pharmaceuticals USA Inc.
USA
Mitomycin 40 mg/80mL

Mitomycin 40 mg/80mL

Mitomycin · 40 mg/80 mL

Mitomycin
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Hikma Pharmaceuticals USA Inc.
USA